11 - BIBLIOGRAFIA · Referências Bibliográficas 123 BUTLER, W. R. & KILBURN, J. O. Susceptibility of Mycobacterium tuberculosis to pyrazinamide and its relationship to pyrazinamidase

Referências Bibliográficas


121

7. REFERÊNCIAS BIBLIOGRÁFICAS

ACOCELLA, G.; CARLONE, N. A.; CUFFINI, A. M.; CAVALLO, G. The penetration of rifampicin, pyrazinamide, and pyrazinoic acid into mouse macrophages. Am Rev Respir Dis. 132: 1268-73, 1985.

AHMED, S. A.; GOGAL, R. M.; WALSH, J. E. A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. J Immunol Methods. 170: 211-24, 1994.

AILY, D. C.; SHIKAMA, M. L. M.; OLIVEIRA, M. L. F.; SILVA, R. M. Perfil bacteriológico da tuberculose pulmonar na região de Campinas e das Diretorias Regionais de Saúde XII, XV e XX – 1999/2000. Rev. Inst. Adolfo Lutz. 62(1): 5-10, 2003.

AÍNSA, J. A.; BLOKPOEL, M. C. J.; OTAL, I.; YOUNG, D. B.; DE SMET, K. A. L.; MARTÍN, C. Molecular cloning and characterization of Tap, a putative multidrug efflux pump present in Mycobacterium fortuitum and Mycobacterium tuberculosis. J Bacteriol 180(22): 5836-43, 1998.

ANGUS, B. J.; YATES, M.; CONTON, C.; BYREN, I. Cutaneous tuberculosis of the penis and sexual transmission of tuberculosis confirmed by molecular typing. Clin Infect Dis Brief Reports 33: 32-4, 2001.

AONO, A.; HIRANO, K.; HAMASAKI, S.; ABE, C. Evaluation of BACTEC MGIT 960 PZA médium for susceptibility testing of Mycobacterium tuberculosis to pyrazinamide (PZA): compared with the results of pyrazinamidase assay and Kyokuto PZA test. Diagn. Microbiol. Infect. Dis. 44: 347-52, 2002.

BAMAGA, M.; WRIGHT, D. J. M.; ZHANG, H. Selection of in vitro mutants of pyrazinamide-resistant Mycobacterium tuberculosis. Internat J Antimicrob Agents. 20: 275-81, 2002.

BANERJEE, A.; DUBNAL, E.; QUEMARD, A.; BALASUBRAMANIAN, K. S.; WILSON, T.; COLLINS, D.; LISLE, G.; JACOBS, W. R. InhA, a gene enconding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science. 263:227-30, 1994.


122

BARRERA, L. Acerca de la resistencia de las micobacterias a los antibióticos, un enfoque microbiológico. Infec & Microbiol Clin, Buenos Aires, 6: 192-8, 1994.

BOSHOFF, H. I. & MIZRAHI, V. Expression of Mycobacterium smegmatis pyrazinamidase in Mycobacterium tuberculosis confers hypersensitivity to pyrazinamide and related amides. J Bacteriol. 182(19): 5479-85, 2000.

BOSHOFF, H. I.; MIZRAHI, V.; BARRY III, C. E. Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I. J Bacteriol. 184(8): 2167-72, 2002.

BOSHOFF, H. I. M.; REED, M. B.; BARRY III, C. E.; MIZRAHI, V. DnaE2 Polymerase Contributes to In Vivo Survival and the Emergence of Drug Resistance in Mycobacterium tuberculosis. Cell. 111(18): 183-93, 2003.

BRASIL. MINISTÉRIO DA SAÚDE. Plano Nacional de Controle da Tuberculose. Brasília, 2003. [on line] Available: http://www.saude.gov.br/programas/tuberculose

BRASIL. MINISTÉRIO DA SAÚDE. SECRETARIA DE VIGILÂNCIA EM SAÚDE. DEPARTAMENTO DE VIGILÂNCIA EPIDEMIOLÓGICA. COORDENAÇÃO GERAL DE DOENÇAS ENDÊMICAS. ÁREA TÉCNICA DE PNEUMOLOGIA SANITÁRIA. Programa Nacional de Controle da Tuberculose. Fevereiro, 2004. p. 3.

BRINDLEY, D. N.; MATSUMURA, S.; BLOCH, K. Mycobacterium phei fatty acid

synthetase a bacterial multienzime complex. Nature. 224: 666-9, 1969.

BROWN, T. J.; TANSEL, Ö.; FRENCH, G. L. Simultaneous identification and typing of multidrug-resistant Mycobacterium tuberculosis isolates by analysis of pncA and rpoB. J Med Microbiol. 49(7): 651-6, 2000.

BUTLER, W. R. & KILBURN, J. O. Improved method for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol. 16(6): 1106-9, 1982.


123

BUTLER, W. R. & KILBURN, J. O. Susceptibility of Mycobacterium tuberculosis to pyrazinamide and its relationship to pyrazinamidase activity. Antimicrob Agents Chemother. 24(4): 600-1, 1983.

CANETTI, G.; RIST, N.; GROSSET, J. Mésure de la sensibilité du bacilli tuberculeux aux drogues antibacilares par la méthode des porportions. Rev. Tuberc. Pneumo., Paris, 27: 217, 1963.

CARDOSO, E. M.; NOVO, M. L.; FONT, M. E.; ÁLVAREZ, J. A. V. Evaluación de la prueba de la pirazinamidasa para la determinación de la susceptibilidad de Mycobacterium tuberculosis a la pirazinamida. Rev Cubana Med Trop. 51(1): 53-4, 1999.

CARDOSO, R. F.; COOKSEY, R. C.; MORLOCK, G. P.; BARCO, P.; CECON, L.; FORESTIERO, F.; LEITE, C. Q. F.; SATO, D. N.; SHIKAMA, M. L.; MAMIZUKA, E. M.; HIRATA, R. D. C.; HIRATA, M. H. Screening and Characterization of Mutations in Isoniazid-Resistant Mycobacterium tuberculosis Isolates Obtained in Brazil. Antimicrob. Agents Chemot. 48(9): 3373-81, 2004.

CAWS, M. & DROBNIEWSKI, F. A. Molecular techniques in the diagnosis of Mycobacterium tuberculosis and the detection of drug resistance. Annals of the New York Academy of Sciences. 953: 138-45, 2001.

Centro de Vigilância Epidemiológica – Secretaria de Estado da Saúde de São Paulo. Tuberculose – Informações divsersas, tabelas e série histórica. 2000. [on line]. Available: http://www.cve.saude.sp.gov.br

Centro de Vigilância Epidemiológica – Secretaria de Estado da Saúde de São Paulo. Tuberculose – Informações divsersas, tabelas e série histórica. 2004. [on line]. Available: http://www.cve.saude.sp.gov.br

CHAN, J. & KAUFMANN, S. H. E. em Tuberculosis: Pathogenesis,

Protection, and Control (ed. Bloom, B. R.) 271-284 .Am. Soc. Microbiol., Washington DC, 1994.

CHENG, S.; THIBERT, L.; SANCHEZ, T.; HEIFETS, L.; ZHANG, Y. pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada. Antimicrob Agents Chemother. 44(3): 528-32, 2000.


124

COHEN, T.; SOMMERS, B.; MURRAY, M. The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Inf Dis. 3: 13-21, 2003.

COHN, D. L.; BUSTREO, F.; RAVIGLIONE, M. C.; Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD Global Surveillance Project. Clin. Infect. Dis., v. 24, p. 121-30, 1997. Supplement 1.

COLE, S. T. Mycobacterium tuberculosis: drug-resistance mechanisms. Trends in Microbiology. 2(10): 411-5, 1994.

COLE, S. T. BROSCH, R.; PARKHILL, J.; GARNIER, T.; CHURCHER, C.; HARRIS, D.; GORDON, S V.; EIGLMEIER, K.; GAS, S.; BARRY III, C. E.; TEKAIA, F.; BADCOCK, K.; BASHAM, D.; BROWN, D.; CHILINGWORTH, T.; CONNOR, R.; DAVIES, R.; DEVLIN, K.; FELTWELL, T.; GENTLES, S.; HAMLIN, N.; HOLROYD, S.; HORNSBY, T.; JAGELS, K.; KROGH, A.; MCLEAN, J.; MOULE, S.; MURPHY, L.; OLIVER, K.; OSBORNE, J.; QUAIL, M. A.; RAJANDREAM, M.-A.; ROGERS, J.; RUTTER, S.; SEEGER, K.; SKELTON, J.; SQUARES, R.; SQUARES, S.; SULSTON, J. E.; TAYLOR, K.; WHITEHEAD, S. & BARREL, B. G. Deciphering the Biology of Mycobacterium tuberculosis from the Complete Genome Sequence. Nature. 393(11): 537-544, 1998.

COLE, S. T. Learning from the genome sequence of Mycobacterium tuberculosis H37Rv. FEBS Letters. 452: 7-10, 1999.

COLLINS, L. A. & FRANZBLAU, S. G. Microplate Alamar Blue Assay versus BACTEC 460 System for High-Throughput Screening of Compuns against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Agents Chemother. 41(5):1004-9, 1997.

CONTE, J. E.; GOLDEN, J. A..; DUNCAN, S.; McKENNA, E.; ZURLINDEN, E.

Intrapulmonary concentrations of pyrazinamide. Antimicrob Agents Chemother. 43: 1329-33, 1999.

COSIVI, O. J.; GRANGE, J. M.; DABORN, C. J.; RAVIGLIONE, M. C.;

FUJIKURA, T.; COUSINS, D.; ROBINSON, R. A.; HUCHZERMEYER, H. F.; de KANTOR, L.; MESLIN, F. X. Zoonotic tuberculosis due to Mycobacterium bovis in developing countries. Emerg Infect Dis. 4: 5970, 1998.


125

COUSINS, D. V.; BASTIDA, R.; CATALDI, A.; QUSE, V.; REDROBE, S.; DOW,

S.; DUIGNAN, P.; MURRAY, A.; DUPONT, C.; AHMED, N.; COLLINS, D. M.; BUTLER, W. R.; DAWSON, D.; RODRÍGUEZ, D.; LOUREIRO, J.; ROMANO, M. I.; ALITO, A.; ZUMARRAGA, M.; BERNARDELLI, A. Tuberculosis in seals caused by a novel member of the Mycobacterium tuberculosis complex: Mycobacterium pinnipedii sp. nov. Intern J System Evolut Microbiol. 53: 1305-14, 2003.

CYNAMON, M. H.; SPEIRS, R. J.; WELCH, J. T. In vitro antimycobacterial activity of 5-chloropyrazinamide. Antimicrob Agents Chemother. 42(2): 462-3, 1998.

DANKNER, W. M.; WAECKER, N. J.; ESSEY, K. M.; THOMPSON, M.; DAVIS, C. E. Mycobacterium bovis infection in San Diego: a clinicoepidemiologic study of 73 patients and a historical review of a forgotten pathogen. Medicine. 72:11-37, 1993.

DAVIES, P. D. O. Multi-drug Resistant Tuberculosis. TB Focus, march, 1999.

DAVIES, A. P.; BILLINGTON, O. J.; MCHUGH, T. D.; MITCHISON, D. A.; GILLESPIE, S. H. Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing with Mycobacterium tuberculosis. J Clin Microbiol. 38(10): 3686-88, 2000.

DESSEN, A.; QUEMARD, A.; BLANCHARD, J.S.; JACOBS Jr., W.R.; SACCHETTINI, J.C. Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis. Science, v.267, p.1638-1641, 1995.

DICKINSON, J. M. & MITCHISON, D. A. Observations in vitro on the suitability of pyrazinamide for intermittent chemotherapy of tuberculosis. Tubercle.51:389-96, 1970.

DYE, C.; SCHEELE, S.; DOLIN, P.; PATHANIA, V.; RAVIGLIONE, M. C. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA, V. 282, p. 677-686, 1999.


126

ENDOH, T.; YAGIHASHI, A.; UEHARA, N.; KOBAYASHI, D.; TSUJI, N.; NAKAMURA, M.; HAYASHI, S. FUJII, N.; WATANABE, N. Pyrazinamide resistance associated with pncA gene mutation in Mycobacterium tuberculosis in Japan. Epidemiol. Infect. 128(2): 337-42, 2002.

ESCALANTE, P.; RAMASWAMY, S.; SANABRIA, H.; SOINI, H.; PAN, X.; VALIENTE-CASTILLO, O.; MUSSER, J. M. Genotypic characterization of drug-resistant Mycobacterium tuberculosis isolates from Peru. Tuber Lung Dis, 79: 111-8, 1998.

FANG, Z.; DOIG, C.; RAYNER, A.; KENNA, D.T.; WATT,B.; FORBES, K.J. Molecular evidence for heterogeneity of the multiple-drug-resistant Mycobacterium tuberculosis population in Scotland (1990 to 1997). J. Clinical microb. v.37, n.4, p.998-1003, 1999.

FERNANDES, N. D. & KOLATTUKUDY, P. E. Cloning, sequencing and characterization of a fatty acid synthase-enconding gene from Mycobacterium tuberculosis variant BCG. Gene. 170:95-9, 1996.

FISCHL, M. A.; DAIKOS, G. L., et al. Clinical Presentation and Outcome of Pacients with HIV Infection and Tuberculosis Caused by Multiple-Drug-Resistant Bacilli. Annals of Internal Medicine. 117: 184-190, 1992.

FIÚZA de MELO, F. A.; AFIUNE, J. B. Transmissão e imunopatologia da Tuberculose. Jornal de Pneumologia, São Paulo, 19(1): 19-24, 1993.

FIÚZA de MELO, F. A.; AFIUNE, J. B.; ALMEIDA, E. A.; SPADA, D. T. A.; CASTELO FILHO, A. Resistência primária do Mycobacterium tuberculosis em um referência na cidade de São Paulo: evolução por quatro décadas. J. Pneumol. Vol. 26 Supl. 2:S130, 2000.

FIÚZA de MELO, F. A.; PENTEADO, C. B.; ALMEIDA, E. A.; SPADA, D. T. A.; SANTOS, M. A. A. Resistência Pós-primária do Mycobacterium tuberculosis às drogas antituberculosas segundo os antecedentes terapêuticos em uma unidade de referência na cidade de São Paulo. Bol. Pneumol. Sanit. 10(2): 21-6, 2002.

FIÚZA de MELO, F. A.; AFIUNE, J. B.; IDE NETO, J.; ALMEIDA, E. A.; SPADA, D. T. A.; ANTELMO, A. N. L.; CRUZ, M. L. Aspectos epidemiológicos da


127

tuberculose multirresistente em serviço de referência na cidade de São Paulo. Rev. Socied. Brasil. Medic. Trop. 36(1): 27-34, 2003.

FRANZBLAU, S. G.; WITZIG, R. S.; MCLAUGHLIN, J. C.; TORRES, P.; MADICO, G.; HERNANDEZ, A.; DEGNAN, M. T.; COOK, M. B.; QUENZER. V. K.; FERGUSON, R. M.; GILMAN, R. H. Rapid, Low-Technology MIC Determination with Clinical Mycobacterium tuberculosis Isolates by Using the Microplate Alamar Blue Assay. J Clin Microbiol. 36(2): 362-6, 1998.

FRIEDEN, T. R.; STERLING, T.; MENDEZ, A. P.; KILBURN, J. O.; CAUTHEN, G. M.; DOOLEY, S. W. The Emergence of Drug-resistant Tuberculosis in New York City. New England Journal of Medicine, v. 328, p. 521-526, 1993.

GONZALEZ-Y-MERCHAND, J. A.; ESTRADA-GARCIA, I.; COLSTON, M. J.; COX, R. A. A novel method for the isolation of mycobacterial DNA. FEMS Microbiol Let. 135: 71-7, 1996.

GOOD, R. C.; SILCOX, V. A.; KILBORN, J. O.; PLIKAYTIS, B. D. Identification and drug susceptibility test results for Mycobacteria species. Clin Microbiol Newslett. 7: 133-6, 1985.

GROENEN, P. M. A.; BUNSCHOTEN, A. E.; Van SOOLINGER, D.; Van EMBDEN, J. D. A. Nature of DNA polymorphism in the direct repeat cluster of Mycobacterium tuberculosis, Aplication for strain differentiation by a novel method. Mol. Microbiol. 10(5): 1057-65, 1993.

GUO, M.; SUN, Z.; ZHANG, Y. Mycobacterium smegmatis has two pyrazinamidase enzymes, pncA and pzaA. J Bacteriol. 182(13): 3881-4, 2000.

HACKBARTH, C. J.; UNSAL, I.; CHAMBERS, H. F. Cloning and Sequence Analysis of a Class A β-Lactamase from Mycobacterium tuberculosis H37Ra. Antimicrobiol Agents Chemother. 41(5): 1182-5, 1997.

HANNAN, M. M.; DESMOND, E. P.; MORLOCK, G. P.; MAZUREK, G. H.; CRAWFORD, J. T. Pyrazinamide-monoresistant Mycobacterium tuberculosis in the United States. J Clin Microbiol. 39(2): 647-50, 2001.


128

HEIFETS, L. & LINDHOLM-LEVY, P. Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations. Am Rev Respir Dis. 145: 1223-5, 1992.

HEIFETS, L. B. Drug susceptibility in the management of chemotherapy of tuberculosis. In: HEIFETS, L. B.; CYNAMON, M. H. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton, CRC Press.. Am Rev Respir Dis p. 89-122, 1991.

HEIFETS, L. B. Drug susceptibility testing in mycobacteriology. In: HEIFETS, L. B. Clinical mycobacteriology. Philadelphia, WB Saundersp. 641-56, 1996.

HEIFETS, L.; HIGGINS, M.; SIMON, B. Pyrazinamide is not active against Mycobacterium tuberculosis residing in cultured human monocyte-derived macrophages. Int J Tuberc Lung Dis 4(6): 491-5, 2000a.

HEIFETS, L. & SANCHEZ, T. New agar medium for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol. 38(4): 1498-1501, 2000b.

HEIFETS, L. Susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J Med Microbiol. 51: 11-2, 2002.

HEYM, B.; ALZARI, P.M.,; HONORÉ, N. AND COLE, S.T. Missense mutations

in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis. Molecular Microbiology, v.15, n.2, p.235-245, 1995.

HEYM, B.; STRAVOPOULOS, E.; HONORE, N.; DOMENECH, P., SAINT-JOANIS, B.; WILSON, T.M.; COLLINS, D.M.; COLSTON, M.J.; COLE, S.T. Effects of overexpression of the alkyl hydroperoxide redutase AhpC on the virulence and isoniazid resistance of Mycobacterium tuberculosis. Infect. Immun., v.65, n.4, p.1395-1401, 1997.

HIGGINS, D. G. & SHARP, P. M. CLUSTAL: a package for performing multiple sequence alignment on a microcomputer. Gene. 73: 237-44, 1988.


129

HIRANO, K.; TAKAHASHI, M.; KAZUMI, Y.; FUKASAWA, Y.; ABE, C. Mutation in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis. Tuber. Lung Dis., v. 78, p. 117-122, 1997.

HOU, L.; OSEI-HYIAMAN, D.; ZHANG, Z.; WANG, B.; YANG, A.; KANO, K. Molecular characterization of pncA gene mutations in Mycobacterium tuberculosis clinical isolates from China. Epidemiol Infect. 124(2): 227-32, 2000.

HUANG, T.; LEE, S. S.; TU, H.; HUANG, W.; CHEN, Y.; HUANG, C.; WANN, S.; LIN, H.; LIU, Y. Correlation between Pyrazinamide activity and pncA mutations in Mycobacterium tuberculosis isolates in Taiwan. Antimicrob. Agents Chemother. 47(11): 3672-3, 2003.

ISEMAN, M. & MADSEN, L. A. Drug-resistant tuberculosis. Clin. Chest. Med., 10: 341, 1989.

JARLIER, V. & NIKAIDO, H. Mycobacterial Cell Wall: Structure and Role in Natural Resistance to Antibiotics. FEMS Microbiol Let. 123: 11-8, 1994.

KAMERBEEK, J.; SCHOULS, L.; KOLK, A.; AGTERVELD, M.; SOOLINGEN, D.; KUIJPER, S.; BUNSCHOTEN, A.; MOLHUIZEN, H.; SHAW, R.; GOYAL, M.; EMBDEN, J. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol. 35(4): 907-14, 1997.

KAPUR, V.; LI, L.L.; HAMRICK, M. R.; PLIKAYTI, B. B.; SHINNICK, T. M.; TELENTI, A. Rapid Mycobacterium species assignment and unambiguous identification of mutations associated with antibiotic resistance in Mycobacterium tuberculosis by automated DNA sequencing. Arch. Pathol. Lab. Med. v. 119, p.131-138, 1995.

KELLEY, C.L.; ROUSE, D.A. AND MORRIS, S.L. Analysis of ahpC gene mutations in isoniazid-resistante clinical isolates of Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. v.41, n. 9, p. 2057-2058, 1997.


130

KENT, P. T. & KUBICA, G. P. Public Health Mycobacteriology. A Guide for the Level III Laboratory. U. S. Department of Health and Human Services. CDC. Atlanta, Georgia, 1985.

KIEHN, T. E.; CYNAMON, M. H.; INDERLIED, C. B.; ROBERTS, G. D.; SIDDIQI, S. H.; WALLACE, R. J.; WARREN, N. G. Antimycobacterial susceptibility testing for Mycobacterium tuberculosis, tentative standard. NCCLS M24-T, 15: 1-31, 1995.

KIKUCHI, S.; RAINWATER, D. L.; KOLATTUKUDI, P. E. Purification and characterization of an usually large fatty acid synthase, from Mycobacterium tuberculosis var. bovis BCG. Arch. Biochem. Biophys. 24, 263-70, 1992.

KLEMENS, S. P.; SHARPE, C. A.; CYNAMON, M. H. Activity of pyrazinamide in a murine model against Mycobacterium tuberculosis isolates with various levels of in vitro susceptibility. Antimicrob Agents Chemother. 40(1): 14-16, 1996.

KOLATTUKUDY, P. E.; FERNANDES, N. D.; AZAD, A. K.; FITZMAURICE, A. M.; SIRAKOVA, A. T. Biochemistry and molecular genetics of cell-wall lipid biosynthesis in mycobacteria. Mol Microbiol. 24: 263-70, 1997.

KONNO, K.; FELDMAN, F. M.; McDERMOTT, W. Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am Rev Respir Dis. 95:461-9, 1967.

KRAEMER, H.; FELTKAMP, U.; BREITHAUPT, H. Quantification of pyrazinamide and its metabolites in plasma by ionic-pair high-performance liquid chromatography. Implications for the separation mechanism. J Chromatog B. 706: 319-28, 1998.

LEE, A.S.G.; TANG, L.L.H.; LIM, I.H.K.; LING, M.L; TAY, L.; WONG, S.Y. Lack of clinical significance for the common arginine-to-leucine substitution at codon 463 of the katG gene in isoniazid-resistant Mycobacterium tuberculosis in Singapore. J. Infect. Diseases. v.176(October), p.1125-1127, 1997.


131

LEE, A.S.G.; LIM, I.H.; TANG, L.L.H.; TELENTI, A.; WONG, S.Y. Contribution of kasA analysis to detection of isoniazid-resistant Mycobacterium tuberculosis in Singapore. Antimicrobial Agents and Chemotherapy. v.43, n.8, p. 2087-2089, 1999.

LEE, A. S. G.; TEO, A. S. M.; WONG, S.Y. Novel mutations in ndh in Isoniazid-Resistant Mycobacterium tuberculosis Isolates. Antimicrobial Agents and Chemotherapy. July, 45(7): 2157-59, 2001a.

LEE, K. W.; LEE, J.; JUNG, K. Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Korea. J Korean Med Sci. 16: 537-43, 2001b.

LEI, B.; WEI, C-J.; TU, S-C. Action Mechanism of Antitubercular Isoniazid.

The Journal of Biological Chemistry, 275(4): 2520-26, 2000.

LEITE, C. Q. F.; BERETTA, A. L. R. Z.; ANNO, I. S.; TELLES, M. A. S. Standardization of Broth microdilution method for Mycobacterium tuberculosis. Mem Inst Oswaldo Cruz. 95(1): 127-9, 2000.

LEMAITRE, N.; SOUGAKOFF, W.; TRUFFOT-PERNOT, C.; JARLIER, V. Characterization of new mutations in pyrazinamide-resistant strains of Mycobacterium tuberculosis and identification of conserved regions important for the catalytic activity of the pyrazinamidase pncA. Antimicrob Agents Chemother. 43(7): 1761-3, 1999.

LEMAITRE, N.; CALLEBAUT, I.; FRENOIS, F.; JARLIER, V.; SOUGAKOFF, W. Study of the structure-activity relationships for the pyrazinamidase (pncA) from Mycobacterium tuberculosis. Biochem J. 353, 453-8, 2001.

MAHMOUDI, A. & ISEMAN, M. D. Pitfalls in the care of patients with tuberculosis – common errors their association with the acquisition of drug resistance. JAMA, v. 270, p. 65-68, n. 1, 1993.

MARTILLA, H. J.; MARJAMÄKI, M.; VYSHNEVSKAYA, E.; VYSHNEVSKIY, B. I.; OTTEN, T. F.; VASILYEF, A. V.; VILJANEN, M. K. pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from Northwestern Russia. Antimicrob Agents Chemother. 43(7): 1764-66, 1999.


132

McCLATCHY, J. K.; TSANG, A. Y.; CERNICH, M. S. Use of pyrazinamidase activity in Mycobacterium tuberculosis as a rapid method for determination of pyrazinamide susceptibility. Antimicrob Agents Chemother. 20(4): 556-7, 1981.

McDERMOTT, W.; TOMPSETT, R. Activation of pyrazinamide and

nicotinamide in acidic environment in vitro. Am Rev Tuberc. 70:748-54, 1954.

MDLULI, K.; SLAYDEN, R.A.; ZHU, Y.; RAMASWAMY, S,; PAN. X. MEAD, D. ;

CRANME, D. D.; MUSSER, J.M.; BARRY III, C.E. Inhibition of a Mycobacterium tuberculosis β-Ketoacyl ACP Synthase by isoniazid. Science. V.280, p.1607-1610, 1998.

MEHMEDAGIC, A.; VÉRITÉ, P.; MÉNAGER, S.; THATASSE, C.; CHABENAT, C.; ANDRÉ, D.; LAFONT, O. Determination of pyrazinamide and its main metabolites in rat urina by high-performance liquid chromatography. J Chromatog B. 695: 365-72, 1997.

MESTDAGH, M.; FONTEYNE, P. A.; REALINI, L.; ROSAU, R.; JANNES, G.; MIJS, W.; DE SMET, K. A. L.; PORTAELS, F.; VAN DEN EECKHOUT, E. Relationship between pyrazinamide resistance, loss of pyrazinamidase activity, and mutations in the pncA locus in multidrug-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 43(9): 2317-19, 1999.

MIESEL, L.; WEISBROD, T. R.; MARCINKEVICIENE, J. A.; BITTMAN, R.; JACOBS Jr, W. R. NADH Dehydrogenase Defects confer Isoniazid Resistance and Conditional Lethality in Mycobacterium smegmatis. J. Bacteriol. May, 180(9): 2459-67, 1998.

MILLER, M. A.; THIBERT, L.; DESJARDINS, F.; SIDDIQI, S. H.; DASCAL, A. Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide: comparison of BACTEC method with pyrazinamidase assay. J Clin Microb. 33(9): 2468-70, 1995.

MIMS, C.; PLAYFAIR, J.; ROITT, I.; WAKELIN, D.; WILLIANS, R. Microbiologia Médica. 2ª ed, Ed. Manole LTDA, São Paulo, 1999.


133

MITCHISON, D. A. The action of antituberculosis drugs in short-course chemotherapy. Tubercle, v. 66, p. 219-225, 1985.

MITCHISON, D. A., NUNN, A. J. Influence of initial drug resistance on the response short course chemotherapy of pulmonary tuberculosis. Am. Rev. Respir. Dis., v. 133, p. 423-30, 1986.

MIYAGI, C.; YAMANE, N.; YOGESH, B.; ANO, H.; TAKASHIMA, T. Genetic and phenotypic characterization of pyrazinamide-resistant Mycobacterium tuberculosis complex isolates in Japan. Diagn. Microbiol. Infect. Dis. 48: 111-6, 2004.

MIZRAHI, V. & ANDERSEN, S. J. DNA Repair in Mycobacterium tuberculosis. What have we learnt from the Genoma Sequence? Mol Microbiol. 29(6): 1331-9, 1998.

MOLHUIZEM, H. O.; BUNSCHOTEN, A. E.; SCHOULS, L. M.; VAN EMBDEN, J. D. A. - Rapid detection and simultaneous strain differentiation of Mycobacterium tuberculosis complex bacteria by Spoligotyping – In: PARISH, T.; STOKER, N. G. Methods in Molecular Biology, vol. 101: Mycobacteria Protocols, Humana Press, Inc. Totowa, NJ. 1998. P. 381-94.

MONTEROS, L. E. E.; GALÁN, J. C.; GUTIÉRREZ, M.; SAMPER, S.; MARÍN, F. G.; MARTÍN, C.; DOMÍNGUEZ, L.; RAFAEL, L.; BAQUERO, F.; GÓMEZ-MAMPASO, E.; BLÁZQUEZ, J. Allele-specific PCR method based on pncA and oxyR sequences for distinguishing Mycobacterium bovis from Mycobacterium tuberculosis: intraspecific M. bovis pncA sequence polymorphism. J Clin Microbiol. 36(1): 239-42, 1998.

MORLOCK, G. P.; CRAWFORD, J. T.; BUTLER, R.; BRIM, S. E.; SIKES, D.; MAZUREK, G. H.; WOODLEY, C. L.; COOKSEY, R. C. Phenotypic characterization of pncA mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 44(9): 2291-5, 2000.

MORRIS, S.; BAI, G.H.; SUFFYS, P.; PORTILHO-GOMES, J.; FAIRCHOK, M.; ROUSE, D. Molecular mechanisms of multiple drug resistance in clinical isolates of Mycobacterium tuberculosis. J. Infefct. Dis. v.171, p.954-960, 1995.


134

MORRIS, S. L. & ROUSE, D. A. The genetics of multiple drug resistance in Mycobacterium tuberculosis and the Mycobacterium avium complex. Res Microbiol. 147(1-2): 68-73, 1996.

MUSSER, J. M. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin Microbiol Rev. 8(4): 496-514, 1995.

MUSSER, J.M.; KAPUR, V.; WILLIAMS, D.L.; KREISWIRTH, B.N.; VAN

SOOLINGEN, D.; VAN EMBDEN, J.D.A. Characterization of the catalase-peroxidase gene (katG) and inhaA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance. The J. Infect. Diseases, v.173, p.196-202, 1996.

NIEMANN, S.; RICHTER, E.; RÜSCH-GERDES, S. Differentiation among members of the Mycobacterium tuberculosis complex by molecular and biochemical features: evidence for two pyrazinamide-susceptible subtypes of M. bovis. J Clin Microbiol. 38(1): 152-7, 2000.

O’REILLY, L. M. & DABORN, C. J. The epidemiology of Mycobacterium bovis infections in animals and man: a review. Tuberc Lung Dis. 76 (Suppl. 1): 1-46, 1995.

OKAMURA, M. N. Perfil epidemiológico dos pacientes com tuberculose atendidos em um hospital geral universitário, 1999-2001. Tese apresentada à Universidade de São Paulo. Faculdade de Saúde pública. Departamento de Epidemiologia para obtenção do grau de Mestre, 2003.

OMS. Oragnization Global Tuberculosis Programme and International Union Against Tuberculosis and Lung Disease: Anti-tuberculosis Drug Resistance in the World. Report No. 2. Prevalence and Trends. WHO/CDS/TB/2000.278. Geneva: World Health Organization, 2000.

PALACI, M.; UEKI, S. Y. M.; CURCIO, M.; TELLES, M. A. S. Quimioterapia da Tuberculose: Fundamentos, Regimes e Resistência Bacteriana. Rev Ciênc Farm. 18(1): 29-40, 1997.


135

PARK, S. K.; LEE, J. Y.; CHANG, C. L.; LEE, M. K.; SON, H. C.; KIM, C. M.; JANG, H. J.; PARK, H. K.; JEONG, S. H. pncA mutations in clinical Mycobacterium tuberculosis isolates from Korea. BMC Infect Dis. 1:4, 2001. Available on line: http://www.biomedcentral.com/1471-2334/1/4

PAYTON, M.; AUTY, R.; DELGODA, R.; EVERET, M.; SIM, E. Cloning and Characterization of Arylamine N-Acetyltransferase Genes from Mycobacterium smegmatis and Mycobacterium tuberculosis: Increased Expression Results in Isoniazid Resistance. J Bacteriol. Feb. 181(4): 1343-47, 1999.

PELOQUIN, C. A..; JARESKO, G. S.; YONG, C. L.; KEUNG, A. C.; BULPITT, A.

E.; JELLIFFE, R. W. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob Agents Chemother. 41: 2670-9, 1997.

PFYFFER, G. E.; AUCKENTHALER, R.; EMBDEN, J. D. A.; SOOLINGEN, D.

Mycobacterium canetti, the smooth variant of M. tuberculosis, isolated from a swiss patient exposed in Africa. Emerg Infec Dis. 4(4): 631-4, 1998.

PIATEK, A. S.; TELENTI, A.; MURRAY, M. R.; EL-HAJJ, H.; JACOBS Jr, W. R.; KRAMER, F. R.; ALLAND, D. Genotipic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons: implications for rapid susceptibility testing. Antimicrob. Agents Chemother. 44: 103-10, 2000.

PORTUGAL, I.; BARREIRO, L.; MONIZ-PEREIRA, J.; BRUM, L. pncA mutations in Pyrazinamide-Resistant Mycobacterium tuberculosis Isolates in Portugal. Antimicrob. Agents Chemother. 48(7): 2736-8, 2004.

RAMASWAMY, S. & MUSSER, J. M. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tub Lung Dis. 79(1): 3-29, 1998.

RASTOGI, N.; POTAR, M.; DAVID, H. L. Pyrazinamide is not effective against intracellulary growing Mycobacterium tuberculosis. Antimicrob Agents Chemother. 32: 287, 1988.


136

RATTAN, A.; KALIA, A.; AHMAD, N. Multidrug-resistant Mycobacterium tuberculosis: molecular perspectives. Emerg Infec Dis. 4(2): 195-209, 1998.

RAYNAUD, C.; LANÉELLE, M.; SENARATNE, R. H.; DRAPER, P.; LANÉELLE, G.; DAFFÉ, M. Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of uptake in addition to lack of pyrazinamidase activity. Microbiol. 145: 1359-67, 1999.

RIEDER, H.L.; CAUTEN, G.; KELLY, G.D., et al. Tuberculosis in the United States. J. Am. Med. Assoc., v. 262, p. 385-89, 1989.

RILEY, R. L. Aerial dissemination of pulmonary tuberculosis. Am J Hyg. 76: 931-41, 1957.

RILEY, R. L.; MILLS, C. C.; NYKA, W.; WEINSTOCK, N.; STOREY, P. B.; SULTAN, L. U.; RILEY, M. C.; WELLS, W. F. Aerial dissemination of pulmonary tuberculosis: a two-year study of contagion in tuberculosis ward. Am J Hyg. 70: 185-96, 1959.

ROSEMBERG, J. Tuberculose: Panorama global, óbices para o seu controle. Secretaria de Saúde do Estado do Ceará. Fortaleza, 1999, 123p.

ROUSE, D.A.; ZHONGMING, L.; BAI, G.H.; MORRIS, S.L. Characterization of katG and inhA of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, v.39, n. 11, p. 2472-2477, 1995.

ROZWARSKI, D. A.; GRANT, G. A.; BARTON, D. H. R.; JACOS Jr, W. R.; SACCHETTINI, J. C. Modification of the NADH of the Isoniazid Target (InhA) from Mycobacterium tuberculosis. Science. 279(2): 98-102, 1998.

SACHAIS, B. S.; NACHAMKINDAGGER, I. I.; MILLS, J. K.; LEONARD, D. G. Novel pncA mutations in pyrazinamide-resistant isolates of Mycobacterium tuberculosis. Mol. Diagn., v. 3, n. 4, p. 229-231, 1998.


137

SALFINGER, M. & HEIFETS, L. Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method. Antimicrob Agents Chemother. 24:600-1, 1988.

SAMBROOK, J.; FRITSCH, E. R.; MANIATIS, T. Commonly used techniques in molecular cloning. In: Molecular cloning: a laboratory manual. 2 ed. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 1989a. cap. 6, p. 6.3 - 6-19.

SAMBROOK, J.; FRITSCH, E. R.; MANIATIS, T. Gel electrophoresis of DNA. In: Molecular cloning: a laboratory manual. 2 ed. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 1989b. E5-E7.

SATO, D. N. Avaliação da atividade antibacteriana in vitro de compostos derivados do ácido isonicotínico frente ao Mycobacterium tuberculosis. Dissertação de Mestrado. Curso de Pós-Graduação em Farmácia, Área de Análises Clínicas, Faculdade de Ciências Farmacêuticas, Universidade de São Paulo, São Paulo, 1998.

SCHAUF, V.; ROM, W. N.; SMITH, K. A.; SAMPAIO, E. P.; MEYN, P. A.;

TRAMONTANA, J. M.; CONH, Z. A.; KAPLAN, G. Cytokine gene activation and modified responsiveness to interleukin-2 (IL-2) in the blood of tuberculosis patients. J Infec Dis. 168:1056-9, 1993.

SCORPIO, A. & ZHANG, Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidaze, cause resistance to the antituberculous drug, pyrazinamide in tubercle bacillus. Nature Med. 2: 662-7, 1996.

SCORPIO, A.; LINDHOLM-LEVY, P.; HEIFETS, L.; GILMAN, R.; SIDDIQI, S.; CYNAMON, M.; ZHANG, Y. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother. 41(3): 540-3, 1997a.

SCORPIO, A.; COLLINS, D.; WHIPPLE, D.; CAVE, D.; BATES, J.; ZHANG, Y. Rapid differentiation of bovine and human tubercle bacilli based on a characteristic mutation in the bovine pyrazinamidase gene. J Clin Microbiol, 35(1): 106-10, 1997b.

SHERMAN, D.R.; MDLULI, K.; HICKEY, M.J.; ARAIN, T.M.; MORRIS, S.L.;

BARRY III, C.E.; STOVER, C.K. Compensatory ahpC gene expression in


138

isoniazid-resistant Mycobacterium tuberculosis. Science, v.272, p.1641-1643, 1996.

SHINNICK, T. M. & GOOD, R. C. Mycobacterial Taxonomy. Eur J Clin Infec Dis. 13(11): 884-901, 1994.

SIDDIQI, S. Radiometric (BACTEC) tests for slowly growing mycobacteria. In: ISENBERG, H. Clinical microbiology procedures handbook. Washington, DC, American Society for Microbiology. 1992. p. 1-25.

SILVA, C. H. R. M. Bacteriologia: um texto ilustrado. Eventos: Rio de Janeiro, 1999. 285p.

SILVA, P. E. A.; BIGI, F.; SANTANGELO, M. P.; ROMANO, I.; MARTÍN, C.; CATALDI, A.; AÍNSA, J. A. Characterization of P55, a multidrug efflux pump in Mycobacterium bovis and Mycobacterium tuberculosis. Antimicrob Agents Chemother 45(3): 800-4, 2001.

SIMONE, P. M. & DOOLEY, S. W. Multidrug-Resistant Tuberculosis. CDC, MMWR, 1994.

SNIDER, D. E.; ROGOWSKI, J.; ZIERSKI, M.; BEK, E.; LONG, M. W. Successful intermittent treatment of smear-positive pulmonary tuberculosis in six months: a cooperative study in Poland. Am. Rev. Respir. Dis., v. 125, p. 265-267, 1982.

SNIDER, D. E.; RAVIGLIONE, M.; KOCHI, A. Global burden of tuberculosis. In: BLOOM, B. R. Tuberculosis: Pathogenesis, Protection, and Control. American Society for Microbiology Press, Washington-D.C. 1994. P. 3-11.

SOCIEDADE BRASILEIRA DE PNEUMOLOGIA E TISIOLOGIA. Alguns dados sobre tuberculose, 2000. [on line]. Available: http://www.nib.unicamp.br/sbpt/dadeptb.html

SOINI, H.; PAN, X.; AMIN, A.; GRAVISS, E. A.; SIDDIQUI, A. MUSSER, J. M. Characterization of Mycobacterium tuberculosis isolates from patients in


139

Houston, Texas, by Spoligotyping. J Clin Microbiol., Washington, 38(2): 669-76, 2000.

SOMOSKOVI, A.; PARSONS, L. M.; SALFINGER, M. The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. Respir Res. 2(3):164-8, 2001.

SOOLINGEN, D.; HOOGENBOEZEM, T.; HAAS, P. E. W.; HERMANS, P. W. M.; KOEDAM, M. A.; TEPPEMA, R. S.; BRENNAN, P. J.; BESRA, G. S.; PORTAELS, F.; TOP, J.; SCHOULS, L. M.; EMBDEN, J. D. A. A novel pathogenic taxon of the Mycobacterium tuberculosis Complex, Canetti: charaterization of na exceptional isolate from Africa. Intern J System Bacteriol. 47(4): 1236-45, 1997.

SPEIRS, R. J.; WELCH, J. T.; CYNAMON, M. H. Activity of n-Propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis: investigations into mechanism of action of and mechanism of resistance to pyrazinamide. Antimicrob Agents Chemother. 39(6): 1269-71, 1995.

SREEVATSAN, S.; ESCALANTE, P.; PAN, X.; GILLIES II, D. A.; SIDDIQUI, S.; KHALAF, C. N.; KREISWIRTH, B. N.; BIFANI, P.; ADAMS, L. G.; FICHT, T.; PERUMAALLA, V. S.; CAVE, M. D.; van EMBDEN, J. D. A.; MUSSER, J. M. Identification of a polymorphic nucleotide in oxyR specific for Mycobacterium bovis. J Clin Microbiol. 34: 2007-10, 1996.

SREEVATSAN, S.; PAN, X.; ZHANG, Y.; KREISWIRTH, B. N.; MUSSER, J. M. Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms. Antimicrob Agents Chemother. 41(3): 636-40, 1997.

SRINAND, S.; PAN, X.; ZHANG, Y.; KREISWIRTH, B. N. et al. Mutation associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms. Antimocrob. Agents Chemother. 636-40, 1997.

STOTTMEIER, K. D.; BEAM, R. E.; KUBICA, G. P. Determination of drug susceptibility of mycobacteria to pyrazinamide in 7H10 agar. Am Rev Respir Dis. 96: 1072-5, 1967.


140

SUN, Z.; SCORPIO, A.; ZHANG, Y. The pncA gene from naturally pyrazinamide-resistant Mycobacterium avium encodes pyrazinamidase and confers pyrazinamide susceptibility to resistant M. tuberculosis complex organisms. Microbiol. 143(Pt 10): 3367-73, 1997.

SUN, Z. & ZHANG, Y. Reduced pyrazinamidase activity and the natural resistance of Mycobacterium kansasii to the antituberculosis drug pyrazinamide. Antimicrob Agents Chemother. 43(3): 537-42, 1999.

SUZUKI, Y.; SUZUKI, A.; TAMARU, A.; KATSUKAWA, C.; ODA, H. Rapid detection of pyrazinamide-resistant Mycobacterium tuberculosis by a PCR-Based in vitro system. J Clin Microbiol. 40(2): 501-7, 2002.

TELENTI, A. Genetics of Drug Resistant Tuberculosis. Thorax. 53: 793-7, 1998.

THOMPSON, J. D.; GIBSON, T. J.; PLEVNIAK, F.; JEANMOUGIN, F.; HIGGINS, D. G. The ClustalX windows interface: flexible atrategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acid Research. 24: 4876-82, 1997.

TRACEVSKA, T.; JANSONE, I.; BAUNANIS, V.; NODIEVA, A.; MARGA, O.; SKENDERS, G. Spectrum of pncA mutations in Multidrug-Resistant Mycobacterium tuberculosis Isolates Obtained in Latvia. Antimicrob. Agents Chemother. 48(8): 3209-10, 2004.

TRIVED, S. S. & DESAI, S. G. Pyrazinamidase activity of Mycobacterium tuberculosis – a test of sensitivity to pyrazinamide. Tubercle. 68: 221-4, 1987.

van RIE, A.; WARREN, R.; RICHARDSON, M.; GIE, R. P.; ENARSON, D. A.; BEYERS, N.; VAN HELDEN, P. D. Classification of Drug-Resistant Tuberculosis in an Epidemic Area. The Lancet. 356(1): 22-5, 2000.

VILCHÈZE, C.; MORBIDONI, H. R.; WEISBROD, T. R.; IWAMOTO, H; KUO, M.; SACCHETTINI, J. C.; JACOBS Jr, W. R. Inactivation of the inhA-Encoded Fatty Acid Synthase II (FASII) Enoyl-Acyl Carrier Protein Reductase Induces Accumulation of the FASI End Products and Cell Lysis


141

of Mycobacterium smegmatis. J Bacteriol., July, 182(14): 4059-67, 2000.

VOGELSTEIN, B. & GILLESPIE, D. Preparative and analytical purification of DNA from agarose. Proc Natl Acad Sci. 76(2): 615-9, 1979.

VOLADRI, R. K. R.; LAKEY, D. L.; HENNIGAN, S. H.; MENZIES, B. E.; EDWARDS, K. M.; KERNODLE, D. S. Recombinant Expression and Characterization of the Major β-Lactamase of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 42(6): 1375-81, 1998.

WADE, M. M.; VOLOKHOV, D.; PEREDELCHUK, M.; CHIZHIKOV, V.; ZHANG, Y. Accurate mapping of mutations of pyrazinamide-resistant Mycobacterium tuberculosis strains with a scanning-frame oligonucleotide microarray. Diagn. Microbiol. Infec. Dis. 49: 89-97, 2004.

WALLIS, R. S.; VJECHA, M.; AMIR-TAHMASSEB, M.; OKWERA, A.;

BYEKWASO, F.; NYOLE, S.; KANEMGERA, S.; MUGERWA, R. D.; ELLNER J. J. Influence of tuberculosis on human immunodeficiency virus (HIV-1): enhanced cytokine expression and elevated beta 2-microglobulin in HIV-1-associated tuberculosis. J Infec Dis. 167: 43-8, 1993.

WAYNE, L. G. Simple pyrazinamidase and urease tests for routine identification of mycobacteria. Am Rev Respir Dis. 109: 147-51, 1974.

WATANABE, M.; SOFUNI, T.; NOHMI, T. Involvement of Cys69 residue in the

catalytic mechanism of N-hydroxyarylamine O-acetyltransferase of Salmonella typhimurium. Sequence similarity at the amino acid level suggests a common catalytic mechanism of acetyltransferase for S. typhimurium and higher organisms. J. Biol. Chem, 267: 8429-36, 1992.

WEBER, W. W. & HEIN, D. W. Arylamine N-acetyltransferases. Pharmacol. Rev. 37: 25-79, 1985.

WHO* Global Tuberculosis Programme. International Union Against Tuberculosis and Lund Disease (IUATIL). Guidelines for surveillance of drugs resistance in tuberculosis. Geneva, WHO; Paris, IUATLD, 1997.


142

WILSON, T.M. & COLLINS, D.M. ahpC, a gene involved in isoniazid resistance of the Mycobacterium tuberculosis complex. Molecular Microbiology, v.19, n 5, p.1025-1034. 1996.

WOODS, G. L.; BROWN-ELLIOT, B. A.; DESMOND, E. P.; HALL, G. S.; HEIFETS, L.; PFYFFER, G. E.; PLAUNT, M. R.; RIDDERHOF, J. C.; WALLACE, R. J. Jr.; WARREN, N. G.; WITEBSKY. Susceptibility testing of Mycobacteria, Nocardia, and other aerobic Actinomycetes; tentative standard-second edition. NCCLS M24-T72, 21: 1-59, 2000.

YAJKO, D. M.; MADEJ, J. J.; LANCASTER, M. V.; SANDERS, C. A.; CAWTHON, V. L.; GEE, B.; BABST, A.; HADLEY, K. Colorimetric Method for Determining MICs of Antimicrobial Agents for Mycobacterium tuberculosis. J Clin Microbiol. 33(9): 2324-7, 1995.

ZHANG, Y. & YOUNG, D. Molecular genetics of drug resistance in Mycobacterium tuberculosis. J Antinicrob Chem. 34: 313-9, 1994.

ZHANG, Y.; SCORPIO, A.; NIKAIDO, H.; SUN, Z. Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of M. tuberculosis to pyrazinamide. J Bacteriol. 181(7): 2044-9, 1999.

ZHANG, Y.; PERMAR, S.; SUN, Z. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J Med Microbiol. 51: 42-9, 2002.

ZHANG, Y.; WADE, M. M.; SCORPIO, A.; ZHANG, H.; SUN, Z. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J. Antimicrob. Chemother. 52(5): 790-5, 2003.

ZHANG, Y. & MITCHISON, D. The curious characteristics of pyrazinamide: a review. Int. J. Tuberc. Lung Dis. 7(1): 6-21, 2003.

ZIMHONY, O.; COX, J. S.; WELCH, J. T.; VILCHÈSE, C.; JACOBS JR, W. R. Pyrazinamide inhibits the eukaryotic- like fatty acid synthetase I (FASI) of M. tuberculosis. Nature Med, 6(8): 1043-7, 2000.

Documents

11 - BIBLIOGRAFIA · Referências Bibliográficas 123 BUTLER, W. R. & KILBURN, J. O. Susceptibility of Mycobacterium tuberculosis to pyrazinamide and its relationship to pyrazinamidase